Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
2,768 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01339871 | Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies | completed | Phase 1 | 152 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 16, 2017 | clinicaltrials |
| NCT02662608 | Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC) | completed | N/A | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT02194374 |
| Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL) |
| withdrawn |
| Phase 1 |
| 0 |
| M.D. Anderson Cancer CenterOTHER |
| 0 |
| Jun 12, 2017 |
| clinicaltrials |
| NCT01205672 | Evaluation of the Molecular Effects of Metformin on the Endometrium in Patients With Endometrial Cancer | completed | Early Phase 1 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 2, 2017 | clinicaltrials |
| NCT02829840 | Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jun 2, 2017 | clinicaltrials |
| NCT01409174 | IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma | terminated | Phase 1 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT01191749 | Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL) | terminated | Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT00478686 | Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine | completed | — | 102 | M.D. Anderson Cancer CenterOTHER | 1 | May 8, 2017 | clinicaltrials |
| NCT01471067 | Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies | completed | Phase 1 | 33 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT02251639 | Diagnostic Aids for Detection and Diagnosis of Oral Cancer | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Apr 27, 2017 | clinicaltrials |
| NCT02961816 | Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Apr 21, 2017 | clinicaltrials |
| NCT01059305 | Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin | terminated | Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 4, 2017 | clinicaltrials |
| NCT00943943 | Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations | completed | Phase 1 | 33 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT02812056 | Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Mar 27, 2017 | clinicaltrials |
| NCT00861406 | Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine | completed | Phase 1 | 38 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT00508144 | Single Agent Alimta in Poor Performance Status in Non-small Cell Lung Cancer | completed | Phase 2 | 64 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 13, 2017 | clinicaltrials |
| NCT01266070 | TKI 258 in Von Hippel-Lindau Syndrome (VHL) | terminated | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 13, 2017 | clinicaltrials |
| NCT02950038 | Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC) | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Feb 13, 2017 | clinicaltrials |
| NCT01038635 | 5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) | completed | Phase 1 / Phase 2 | 94 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT01485536 | A Study of the HSP90 Inhibitor AUY922 | terminated | Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 23, 2017 | clinicaltrials |
| NCT02165995 | Use of Navigated Transcranial Magnetic Stimulation (nTMS) in Generated Motor and Language Mapping to Evaluate Brain Recovery Following Surgery | withdrawn | N/A | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Dec 29, 2016 | clinicaltrials |
| NCT00966277 | Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients | completed | Phase 4 | 87 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 12, 2016 | clinicaltrials |
| NCT01619774 | An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor | completed | Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 12, 2016 | clinicaltrials |
| NCT01007058 | Markers of Response to Intravesical Bladder Cancer Therapy | completed | — | 150 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 7, 2016 | clinicaltrials |
| NCT02420938 | Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Dec 6, 2016 | clinicaltrials |
| NCT01508273 | Lifestyle Intervention for High Risk Cancer Survivors | completed | N/A | 1,150 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 2, 2016 | clinicaltrials |
| NCT01162785 | 1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer | completed | Phase 1 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 28, 2016 | clinicaltrials |
| NCT00495950 | Prospective Measurement of Post-Treatment Lymphedema | completed | — | 350 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 25, 2016 | clinicaltrials |
| NCT02645591 | Randomized AmnioFix Study During Radical Prostatectomy | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Nov 22, 2016 | clinicaltrials |
| NCT00081159 | Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases | completed | Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 10, 2016 | clinicaltrials |
| NCT00499603 | Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer | unknown | Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 1, 2016 | clinicaltrials |
| NCT01396499 | Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias | completed | Phase 1 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 1, 2016 | clinicaltrials |
| NCT00526110 | Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients | completed | Phase 1 / Phase 2 | 98 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2016 | clinicaltrials |
| NCT00891618 | Acupuncture for Chemo-Induced Peripheral Neuropathy | completed | Phase 2 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2016 | clinicaltrials |
| NCT01113463 | TPI 287 in Patients With Recurrent Glioblastoma Multiforme | terminated | Phase 2 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2016 | clinicaltrials |
| NCT00833625 | FDG-PET-CT and Biomarkers in Esophageal Cancer | completed | N/A | 31 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 28, 2016 | clinicaltrials |
| NCT00592462 | Whole Body Magnetic Resonance Imaging (MRI) for Detection of Cancer Metastases | completed | — | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 27, 2016 | clinicaltrials |
| NCT01039844 | Study of Weekly LOC-paclitaxel Injection for Melanoma | terminated | Phase 1 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 27, 2016 | clinicaltrials |
| NCT00933426 | Lenalidomide and Paclitaxel in Prostate Cancer | terminated | Phase 1 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 26, 2016 | clinicaltrials |
| NCT01479179 | Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Oct 26, 2016 | clinicaltrials |
| NCT00714103 | 8-Chloro-Adenosine in Chronic Lymphocytic Leukemia | completed | Phase 1 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 13, 2016 | clinicaltrials |
| NCT00750737 | Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC) | completed | Phase 3 | 46 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 29, 2016 | clinicaltrials |
| NCT00310115 | Motivational Counseling in Preventing Smoking Relapse After Pregnancy in Pregnant Women Who Quit Smoking During Pregnancy | completed | — | 469 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 23, 2016 | clinicaltrials |
| NCT00800839 | Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide | completed | Phase 2 | 56 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 19, 2016 | clinicaltrials |
| NCT01076335 | Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer | completed | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 19, 2016 | clinicaltrials |
| NCT01985477 | Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2016 | clinicaltrials |
| NCT00965341 | Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients | completed | Phase 3 | 53 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 13, 2016 | clinicaltrials |
| NCT01092728 | Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma | terminated | Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 5, 2016 | clinicaltrials |
| NCT00877773 | Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients | terminated | Phase 1 / Phase 2 | 44 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2016 | clinicaltrials |
| NCT01808677 | Registry Study of Thoracic Reirradiation for Non-Small Cell Lung Cancer (NSCLC) Utilizing Proton Beam Therapy or Intensity Modulated Radiation Therapy | completed | — | 49 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 24, 2016 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials